Attovia Therapeutics, Inc. (NASDAQ:ATTO - Get Free Report) major shareholder Redmile Group, Llc bought 200,000 shares of the firm's stock in a transaction on Thursday, August 6th. The shares were purchased at an average price of $17.00 per share, for a total transaction of $3,400,000.00. Following the purchase, the insider owned 982,854 shares in the company, valued at $16,708,518. This trade represents a 25.55% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Large shareholders that own at least 10% of a company's stock are required to disclose their sales and purchases with the SEC.
Redmile Group, Llc also recently made the following trade(s):
- On Thursday, August 6th, Redmile Group, Llc purchased 400,000 shares of Attovia Therapeutics stock. The stock was purchased at an average price of $17.00 per share, with a total value of $6,800,000.00.
Attovia Therapeutics Stock Down 1.6%
Shares of NASDAQ ATTO opened at $19.84 on Tuesday. Attovia Therapeutics, Inc. has a 1 year low of $18.50 and a 1 year high of $22.79.
Institutional Investors Weigh In On Attovia Therapeutics
An institutional investor recently raised its stake in Attovia Therapeutics stock. BlackRock Inc. raised its holdings in shares of Attovia Therapeutics, Inc. (NASDAQ:ATTO - Free Report) by 23.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 164,358 shares of the company's stock after acquiring an additional 31,189 shares during the quarter. BlackRock Inc.'s holdings in Attovia Therapeutics were worth $317,000 as of its most recent SEC filing.
Attovia Therapeutics Company Profile
(
Get Free Report)
Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company's research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.
Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
